<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04266080</url>
  </required_header>
  <id_info>
    <org_study_id>20-040</org_study_id>
    <nct_id>NCT04266080</nct_id>
  </id_info>
  <brief_title>Game-Based Physical Activity in Childhood Cancer Survivors</brief_title>
  <official_title>Assessing a Game-Based Physical Activity Intervention in Childhood Cancer Survivors: The STEP UP for FAMILIES Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sohn Conference Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether a game-based exercise plan can help increase the level of&#xD;
      physical activity in childhood cancer survivors. The game-based exercise plan will involve&#xD;
      participation by both a childhood cancer survivor and his/her parent or caregiver. This study&#xD;
      will also look at whether the game-based exercise plan improves childhood cancer survivors'&#xD;
      quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single-arm pilot study.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptability of the intervention</measure>
    <time_frame>3 months</time_frame>
    <description>(i.e., all four responses on the AIM rates as either a 4 or 5 on a 5-point Likert scale of acceptability);</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>step count</measure>
    <time_frame>3 months</time_frame>
    <description>step count by FitBit-type devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hours of sleep per night</measure>
    <time_frame>3 months</time_frame>
    <description>by FitBit-type devices</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Survivors of Childhood Cancer</condition>
  <arm_group>
    <arm_group_label>childhood cancer survivors &amp; and one parent/legal guardian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study plans to recruit 30 childhood cancer survivors and a parent/legal guardian for each survivor. Participants will be provided with a Fitbit Inspire HR wearable device to record their step counts for two weeks pre-intervention, and over the six-month follow-up period (3-month intervention and 3month follow-up).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fitbit Inspire HR</intervention_name>
    <description>assessing step counts</description>
    <arm_group_label>childhood cancer survivors &amp; and one parent/legal guardian</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionaires</intervention_name>
    <description>Patient-Reported Outcomes Measurement Information System (PROMIS)</description>
    <arm_group_label>childhood cancer survivors &amp; and one parent/legal guardian</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Childhood cancer survivor:&#xD;
&#xD;
          -  History of treatment for childhood cancer with cardiotoxic therapy (anthracyclines,&#xD;
             chest radiation, total body irradiation)&#xD;
&#xD;
          -  Off all systemic cancer therapy for â‰¥ 2 years&#xD;
&#xD;
          -  Ability to speak and understand English&#xD;
&#xD;
          -  Ability to complete all protocol assessments&#xD;
&#xD;
          -  Mobile device with SMS text messaging capability&#xD;
&#xD;
          -  Ambulatory and able to perform all study requirements&#xD;
&#xD;
          -  Attained age 10-16 years&#xD;
&#xD;
          -  Has a parent or legal guardian willing to participate in the study as a dyad&#xD;
&#xD;
          -  Willing to receive daily SMS text message alerts&#xD;
&#xD;
          -  Not currently exercising at least 30 minutes per day (5 days/week)&#xD;
&#xD;
          -  ECOG Performance Status of 0-1&#xD;
&#xD;
        Parent/legal guardian:&#xD;
&#xD;
          -  Parent or legal guardian of a childhood cancer survivor treated with cardiotoxic&#xD;
             therapy (anthracyclines, chest radiation, total body irradiation)&#xD;
&#xD;
          -  Parent or legal guardian of a child age 10-16 years who is at least 2 years from&#xD;
             completion of systemic cancer therapy&#xD;
&#xD;
          -  Ability to speak and understand English&#xD;
&#xD;
          -  Ability to complete all protocol assessments&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Ambulatory and able to perform all study requirements&#xD;
&#xD;
          -  Access to a mobile device with SMS text messaging capability&#xD;
&#xD;
          -  Is the parent or legal guardian of a childhood cancer survivor who is willing to&#xD;
             participate in this study as a dyad&#xD;
&#xD;
          -  Willing to receive daily SMS text message alerts&#xD;
&#xD;
          -  ECOG Performance Status of 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Survivors, or parents/legal guardians of survivors, with a medical condition that&#xD;
             makes it unsafe to complete study requirements are not eligible for this study. This&#xD;
             includes a diagnosis of:&#xD;
&#xD;
               -  Severe persistent asthma&#xD;
&#xD;
               -  Known symptomatic coronary artery disease&#xD;
&#xD;
               -  Musculoskeletal defects that interfere with sustained physical activity&#xD;
&#xD;
               -  Any medical or psychosocial condition that, in the opinion of the investigator,&#xD;
                  would jeopardize the health of the participant during study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danielle Friedman, MD</last_name>
    <phone>212-639-7376</phone>
    <email>friedmad@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Sands, PsyD</last_name>
    <phone>646-888-0023</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Friedman, MD</last_name>
      <phone>646-888-4247</phone>
    </contact>
    <contact_backup>
      <last_name>Stephen Sands, PsyD</last_name>
      <phone>646-888-0023</phone>
    </contact_backup>
    <investigator>
      <last_name>Claire Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Game-Based</keyword>
  <keyword>Physical Activity</keyword>
  <keyword>20-040</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

